Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Maryland Oncology Hematology PA
mi
from
Columbia, MD
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Univ of Minnesota
mi
from
Minneapolis, MN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Missouri Cancer Associates
mi
from
Columbia, MO
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Missouri Baptist Medical Center
mi
from
St. Louis, MO
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Missouri Baptist Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Frontier Cancer Center and Blood Institute
mi
from
Billings, MT
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Frontier Cancer Center and Blood Institute
mi
from
Billings, MT
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
UNM Cancer Center
mi
from
Albuquerque, NM
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
UNM Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
New York Oncology Hematology PC
mi
from
Albany, NY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Sciode Medical Associates, PLLC, d.b.a. Eastchester Center for Cancer Care
mi
from
Bronx, NY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Sciode Medical Associates, PLLC, d.b.a. Eastchester Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Monte fiore
mi
from
Bronx, NY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Monte fiore
mi
from
Bronx, NY
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
DUMC, Duke South
mi
from
Durham, NC
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
DUMC, Duke South
mi
from
Durham, NC
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Sanford Research/USD
mi
from
Fargo, ND
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Sanford Research/USD
mi
from
Fargo, ND
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Cincinnati
mi
from
Cincinnati, OH
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Comprehensive Breast Cancer
mi
from
Columbus, OH
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Comprehensive Breast Cancer
mi
from
Columbus, OH
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Medical Oncology Associates of Wyoming Valley, PC
mi
from
Kingston, PA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Medical Oncology Associates of Wyoming Valley, PC
mi
from
Kingston, PA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Sanford Research/USD
mi
from
Sioux Falls, SD
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Sanford Research/USD
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
The West Clinic, PC
mi
from
Memphis, TN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Abilene
mi
from
Abilene, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Abilene
mi
from
Abilene, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology - Austin Midtown
mi
from
Austin, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology- Denton South
mi
from
Denton, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology- Denton South
mi
from
Denton, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology - Memorial City
mi
from
Houston, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology- Lewisville
mi
from
Lewisville, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology- Lewisville
mi
from
Lewisville, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Mesquite
mi
from
Mesquite, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Midland Allison Cancer Center
mi
from
Midland, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Midland Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology, P.A. - Plano
mi
from
Plano, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology, P.A. - Plano
mi
from
Plano, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology - Sherman
mi
from
Sherman, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Texas Oncology-Tyler
mi
from
Tyler, TX
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Virginia
mi
from
Charlottesville, VA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
mi
from
Salem, VA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
mi
from
Salem, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Virginia Mason Medical Center
mi
from
Seattle, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cancer Care Northwest
mi
from
Spokane, WA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Cancer TEAM Bellin Health
mi
from
Green Bay, WI
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Cancer TEAM Bellin Health
mi
from
Green Bay, WI
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Arizona Oncology Associates, PC- NAHOA
mi
from
Flagstaff, AZ
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Arizona Oncology Associates, PC- NAHOA
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pasadena, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pasadena, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of California at San Francisco
mi
from
San Francisco, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Miami School of Medicine
mi
from
Miami, FL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials